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Mutations in the orphan nuclear receptor DAX-1 cause
X-linked adrenal hypoplasia congenita. Affected boys usually
presentwithprimaryadrenalfailureinearlyinfancyorchild-
hood. Impaired sexual development because of hypogonado-
tropic hypogonadism becomes apparent at the time of pu-
berty. We report adult-onset adrenal hypoplasia congenita in
a patient who presented with hypogonadism at 28 yr of age.
Although he had no clinical evidence of adrenal dysfunction,
compensated primary adrenal failure was diagnosed by bio-
chemicaltesting.Semenanalysisshowedazoospermia,andhe
did not achieve fertility after 8 months of treatment with go-
nadotropins. A novel Y380D DAX-1 missense mutation, which
causes partial loss of function in transient gene expression
assays, was found in this patient. This case demonstrates that
partial loss-of-function mutations in DAX1 can present with
hypogonadotropic hypogonadism and covert adrenal failure
in adulthood. Further, an important role for DAX-1 in sper-
matogenesisinhumansisconfirmed,supportingfindingsin
the Dax1 (Ahch) knockout mouse. (J Clin Endocrinol Metab
87: 44–48, 2002)
T
HE ORPHAN NUCLEAR receptor DAX-1 plays a cru-
cialroleinthedevelopmentandfunctionoftheadrenal
gland and hypothalamic-pituitary gonadal axis (1–4). Mu-
tations in the gene encoding DAX-1 (AHC) cause X-linked
adrenal hypoplasia congenita (AHC) (OMIM: 300200) (1, 2).
Boys with this condition usually present with primary ad-
renal failure in early infancy or childhood (5). Hypogonad-
otropic hypogonadism (HHG), an associated feature of this
disorder,usuallybecomesapparentduringadolescencewith
impaired or arrested pubertal development. Evidence from
Ahch (Dax1) knockout mice (6), and a limited number of
patients with AHC (7, 8), suggests that mutations in DAX-1
may cause abnormalities in spermatogenesis, too.
Following the description of isolated HHG in a woman
who is homozygous for a DAX1 gene mutation (9) and a
report of adult-onset AHC in a patient who presented with
mild adrenal failure and partial HHG (8), we considered
DAX1 as a candidate gene in patients with HHG or delayed
puberty alone. Analysis of more than 100 patients with these
conditionsfailedtorevealanyDAX1genemutations,andwe
concluded that abnormalities in DAX-1 are uncommon in
patients with hypogonadism in the absence of clinical signs
or a family history of adrenal failure (10).
WenowreportanadultmalewithpartialHHGandcovert
compensated adrenal failure because of a novel missense
mutation in DAX1. This case highlights that hypogonadism
maybethepresentingfeatureofX-linkedAHCinadulthood.
Although rare, this diagnosis should still be considered in
young men presenting with hypogonadism, and tests of ad-
renal function and analysis of DAX1 should be performed
when considered appropriate.
Materials and Methods
DNA sequence analysis
After obtaining approval of the local ethical committee, DNA was
extracted from the patient’s blood leukocytes using standard methods.
The DAX1 gene was PCR amplified using primer pairs and conditions
described previously (10). Sequencing reactions were performed in for-
ward and reverse directions using the Taq Big Dye Terminator sequenc-
ing kit and an ABI-PRISM 310 automated DNA sequencer (PE Applied
Biosystems, Foster City, CA).
Construction of DAX1 expression vectors
DAX-1 expression vectors containing the Y380D mutation were cre-
ated by overlapping PCR, using methods described previously (8, 11).
Expression vectors containing wild-type DAX1, the L381H missense
mutant (12), a naturally occurring I439S missense mutant found in a
patient with adult-onset X-linked (8), and a deletion of the carboxy-
terminal region of DAX-1 (del 448–470) were used as positive and
negative controls for DAX-1 function, as reported previously (8, 11).
Abbreviations: AHC, Adrenal hypoplasia congenita; DBD, DNA-
binding domain; Egr-1, early growth response-1; HHG, hypogonado-
tropic hypogonadism; LBD, ligand-like binding domain.
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The effect of the Y380D mutation on basal transcriptional activity by
DAX-1 was investigated using a modified mammalian two-hybrid sys-
tem(8,13).Thecarboxy-terminalregionofDAX-1(codons207–470)was
linked to a GAL4 DNA-binding domain (DBD) in a pBIND expression
vector (Promega Corp., Madison, WI) to allow expression of wild-type
and mutant GAL4-DAX-1 fusion proteins. These expression vectors (50
ng) were cotransfected with a UAS-TK109luc reporter (500 ng) (13).
SF-1-mediated transactivation
TheeffectofDAX-1anditsmutantsonSF-1-mediatedtransactivation
was studied using full-length wild-type or mutant DAX1 cDNA in a
pCMX expression vector. The ligand-like binding domain (LBD) of
human SF-1 (FTZF1) (codons 133–461) was linked to GAL4DBD in
pBIND. These expression vectors (20 ng SF-1, 50 ng DAX-1) were co-
transfected with a UAS-TK109luc reporter (500 ng) (13).
SF-1/early growth response-1 (Egr-1) synergistic activation
of LH
The effect of the Y380D mutant DAX-1 on SF-1/Egr-1 synergistic
activationoftheLHpromoterwasstudiedbycotransfectingfull-length
human wild-type or mutant pCMXDAX-1 (50 ng), full-length human
pCMXSF-1(20ng),andfull-lengthratEgr-1(20ng)withapA3luciferase
reporter (500 ng) containing nucleotides 154 to 5 of the native rat
LH promoter (14).
Transient gene expression assays
Transient gene expression studies were performed by using human
embryonickidneytsa201cellsgrowninDMEMsupplementedwith10%
FBS and 1% streptomycin/penicillin in a 5% CO2 atmosphere at 37 C.
All transfections were performed in triplicate using calcium phosphate
precipitation as described previously (8, 11). Results are expressed as
mean  sem.
Results
Case report
The proband was referred at 28 yr of age with suspected
hypogonadism. Although he reported no concerns about his
libido, physical examination revealed underdeveloped sec-
ondary sexual characteristics, small testes (5 ml bilaterally),
and a eunuchoidal habitus. There was no positive family
history of endocrine disorders.
Endocrine evaluation showed low T (between 1.8 and 2.2
nmol/liter) in the presence of detectable levels of gonado-
tropins (LH 4.4 IU/liter; FSH 5.9 IU/liter) and an impaired
gonadotropin response to repeated GnRH stimulation (100
g gonadorelin, iv) (Fig. 1 and Table 1). Serum PRL (170
mU/liter), E2 (0.12 nmol/liter), and thyroid function were
within the normal range. Olfaction and pituitary magnetic
resonance imaging scans were normal, and his karyotype
was 46,XY. Semen analysis revealed azoospermia on two
separate occasions. Treatment with exogenous gonadotro-
pins (human CG, 5000 IU and Human Menopausal Gonad-
otropin,150IUtwiceweekly)for8monthsresultedinfurther
development of his sexual characteristics and normalization
of serum T levels but produced no improvement in semen
analysis. Consequently, intramuscular T enanthate (250 mg
every 4 wk) replacement was started.
Unexpectedly, initial endocrine investigations also re-
vealed evidence of compensated primary hypoadrenalism.
Serum ACTH was elevated (1800 pg/ml), serum and 24-h
urinaryfreecortisolwerewithinthelowerpartofthenormal
range (serum cortisol, 150 nmol/liter; normal range, 140–
700;urinarycortisol,58nmol/24h,normalrange35–270).No
serum cortisol response was obtained following cosyntropin
stimulation (250 g iv) (142 nmol/liter at 30 min, 136 nmol/
liter at 60 min). Serum electrolytes, aldosterone, and plasma
reninactivity(PRA)werewithinthenormalrangeatthetime
of diagnosis. Physical examination showed no evidence of
hyperpigmentation and blood pressure was normal. An ab-
dominal computed tomography scan revealed small adrenal
glands. Antiadrenocortical antibodies were negative and
very long chain fatty acids were normal. Treatment with
cortisone acetate was started (25 mg total daily). Reevalua-
tion 2 yr later (following withdrawal of glucocorticoid re-
placement for 1 wk) revealed evidence of mild mineralocor-
ticoid deficiency with low-normal serum aldosterone and
increased PRA (6 ng/ml per hour, normal range 0.2–2.7
ng/ml per hour).
Mutational analysis
DNA sequencing of the AHC (DAX1) gene revealed a
hemizygous Y380D missense mutation in DAX-1 in the pro-
band. His mother was heterozygous for this substitution.
ThisY380Dchangeisunlikelytobeapolymorphismbecause
it was not detected in more than 200 alleles screened. The
affected tyrosine is highly conserved in DAX-1, the related
nuclear receptor, and short heterodimer partner and lies
within a cluster of mutations within the carboxy-terminal
region of the protein (Fig. 2).
Transient gene expression assays
Introduction of the Y380D mutation into DAX-1 resulted
in partial loss of DAX-1-mediated repression in all the tran-
sient gene transcription assays tested (Figs. 3 and 4).
In studies of basal transcription, the Y380D and I439S
FIG. 1. Gonadotropin response to repeated GnRH stimulation. Ar-
rows indicate each GnRH injection: a bolus of GnRH given every 2 h.
The values on the graph indicate peaks from multiple samples.
TABLE 1. Biochemical features of the patient with adult-onset
X-linked AHC due to a Y380D missense mutation in DAX-1
DAX1
mutation
Cortisol
(nmol/liter)
ACTH
(pg/mliter)
T
(nmol/liter)
LH/FSH
(IU/liter)
Peak
LH/FSH
(IU/liter)
Y380D 150 1800 2.2 4.4/5.9 4.3/6.2
Normal 140–700 10–60 10–35 0.2–6/0.5–85 –25
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activity,respectively,comparedwiththemoreprofoundloss
of repression seen with the early-onset L381H mutant (43%)
and carboxy-terminal deletion (del448–470) mutant (52%)
(Fig. 3).
As a repressor of SF-1-mediated transcriptional activation,
Y380D and I439S had 90% and 85% of wild-type activity,
compared with 43% and 23% for the severe L381H and car-
boxy-terminal mutants (Fig. 4A).
Finally, in the study of SF-1/Egr-1-mediated synergistic
activation of the LH promoter, Y380D and I439S had 89%
and 94% of wild-type repressor activity, compared with 48%
and 65% for the mutations associated with a more severe
phenotype (Fig. 4B).
Thus,ineachoftheseassaysofDAX-1function,theY380D
mutant exhibits partial loss of function, compared with
DAX-1 mutants associated with more severe clinical
phenotypes.
Discussion
The association of mutations in the orphan nuclear recep-
tor DAX-1 with X-linked AHC and HHG is well established.
Affected boys often present with salt-wasting primary ad-
renal insufficiency in early infancy (5, 15, 16). Children who
do not present early in life tend to present more insidiously
throughout childhood (5, 15). Although abnormal puberty
owing to a combined hypothalamic and pituitary form of
HHG is usually evident about the expected time of puberty
(17), several reports have described normal hypothalamic-
gonadotrope-Leydig cell axis function in infants with this
condition (the so called minipuberty of infancy) (12, 15, 18,
19). Thus, abnormalities in the hypothalamic-gonadotrope
axis may develop only later in life.
Late-onset X-linked AHC has also been described in a
patient who presented with mild adrenal failure at 28 yr of
age (8). He was found to have an I439S missense mutation in
DAX-1. Although he had evidence of partial HHG on pre-
sentation (impaired libido, normal penile length, 6 ml-testes,
low basal T of 5.8–8.4 nmol/liter), a moderate gonadotropin
response to bolus and repeated GnRH stimulation was dem-
onstrated and he reported having sexual intercourse. Symp-
toms of adrenal failure (fatigue, weight loss, orthostatic diz-
ziness) over a 5-yr period led him to seek medical attention,
rather than concerns about his reproductive function.
The patient described here was referred to an endocrinol-
ogistwithhypogonadismat28yrofage.Nopersonalhistory
of hypoadrenalism was reported and there was no family
history of note. He was found to have a hemizygous Y380D
mutation in DAX-1. Compared with the previous case of
late-onset X-linked AHC, this patient (Y380D) has a more
severe reproductive phenotype with a complete lack of go-
nadotropin response to bolus GnRH stimulation (Fig. 1) and
gonadotropin-resistant azoospermia. This case confirms that
an adult-onset form of X-linked AHC can occur, and that
concern about reproductive function may be the presenting
feature rather than symptoms of adrenal failure. The partial
loss of function of the Y380D mutant in transient gene ex-
FIG. 2. The Y380D mutation affects a highly conserved amino acid in
DAX-1(bold)(26).Anasteriskdenotesotheraminoacidsinthisregion
in which mutations have been found in patients with early-onset
X-linked AHC [cluster region II (11)].
FIG. 3. A, Several DAX-1 mutant expression vectors were created by
site-directed mutagenesis for use in functional studies. In particular,
we used two naturally occurring missense mutations (L381H and
I439S) and an artificial C-terminal deletion mutant as control. The
L381H and the C-terminal deletion mutants are known to cause
severe DAX-1 loss of function, and I439S has been shown to be as-
sociated with a less severe impairment of DAX-1 repressor activity.
B, The Y380D missense mutation shows partial loss of DAX-1 re-
pressor activity in a transient gene expression assay of basal tran-
scriptional activity. For this experiment we used 50 ng of a pBIND
vector containing the putative LBD (207–470) of DAX-1 fused to the
GAL4 DBD and 500 ng of a UAS-TK109luc reporter. Transient trans-
fection studies were performed in triplicate using human tsa201 em-
bryonic kidney cells. Data for each mutant are presented as a per-
centage (SEM) of empty vector activity (100%).
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this patient.
We have addressed the issue of a predominant reproduc-
tive phenotype because of DAX1 mutations previously (10).
Following the report of isolated HHG in the absence of ad-
renal failure in a woman who is homozygous for a DAX1
mutation through probable gene conversion (9), we consid-
ered DAX1 as a candidate gene in patients with isolated
HHGorconstitutionaldelayofpuberty.TheDAX1genewas
sequenced in more than 100 patients (95 males, 11 females)
withtheseconditions,butnomutationswerefound(10).The
case described here shows that patients with DAX1 muta-
tions can present with a reproductive phenotype, and the
measurement of ACTH and PRA might be considered in
these cases. However, we know from our previous studies
that such a presentation is relatively rare.
Evidence from overexpression of DAX1/Dax1 in humans
(20) and mice (21) has shown that this nuclear receptor plays
akeydosage-sensitiveroleingonadaldevelopment.Further,
targeted deletion of Dax1 (Ahch) in the mouse causes im-
paired spermatogenesis and infertility (6). Dax1 knockout
mice have quite marked abnormalities of testicular structure
with dilated seminiferous tubules, blockage of the rete testis,
and proximal/middle efferent tubules because of aberrantly
locatedSertolicellsandectopicandhyperplasticLeydigcells
(22). Sertoli cell “rescue” of Dax1 expression has been per-
formed by crossing Dax1 knockout mice with a transgenic
line that express Dax1 from a Mu ¨llerian inhibiting substance
promoter (23). These rescued animals have restored fertility,
but the abnormalities in testicular architecture persist. Fur-
ther, Dax1 knockout mice have marked up-regulation of
testicular aromatase activity, elevated intratesticular E2, and
elevated serum E2 and PRL (24). Of note, serum E2 and PRL
in this patient were normal.
Limited data are available about the role of DAX-1 in
human fertility. Azoopermia has been reported in several
patients with classic X-linked AHC, and attempts to induce
fertility using gonadotropins have been unsuccessful to date
(7, 8). The patient with the I439S mutation and late-onset
X-linked AHC had oligospermia, consistent with his partial
reproductivephenotype.Again,littleimprovementwasseen
following gonadotropin treatment (8). The case presented
here (Y380D) provides further evidence that DAX-1 affects
spermatogenesis and that these patients may be relatively
resistant to gonadotropin treatment. Additional reports of
reproductive function in patients with DAX1 mutations are
important so that appropriate counseling can be provided
and alternative approaches to fertility management such as
intracytoplasmic sperm injection may be considered.
Missense mutations in DAX-1 are relatively rare. Approx-
imately15missensemutationsinDAX-1havebeenreported,
and these appear to cluster within specific regions of the
putative LBD (11). The Y380D mutation affects a tyrosine in
cluster region II, which is highly conserved in DAX-1 from
other species (Fig. 2). Mutation of an amino acid (L381H)
adjacent to this codon has been reported in a patient with
classic early-onset adrenal failure (12). This L381H mutation
causes severe loss of function in gene transcription studies
(Figs. 3 and 4). These amino acids are predicted to lie within
the hydrophobic core of the putative LBD (11, 25), although
the exact structural significance of mutations in this region
will not be revealed until the crystal structure of DAX-1 is
solved. However, the partial loss of DAX-1 repression seen
in functional studies with the Y380D and I439S mutants is
clearly consistent with the late-onset phenotype in these pa-
tients and contrasts with the lack of a genotype-phenotype
correlation for DAX-1 mutations associated with an earlier-
onset classical phenotype (11).
The identification of a Y380D missense mutation in DAX-1
inamanreferredwithhypogonadismat28yrofageconfirms
that a late-onset form of X-linked AHC exists and that pa-
tients can present with a predominant reproductive rather
than adrenal phenotype. The diagnosis of covert compen-
sated primary adrenal failure in this patient has important
clinical implications, especially given the apparent develop-
mentofimpairedmineralocorticoidfunctionwithtime.Most
diagnoses of X-linked AHC are made in the pediatric endo-
FIG. 4. The effect of the Y380D missense mutation on DAX-1 repres-
sor activity in transient gene expression assays of SF-1 mediated
transcriptional activation (a) and SF-1/Egr-1 mediated synergistic
activation of the native LH promoter (b). A, Transfections were
performedusing20ngofapBINDGAL4fusionproteincontainingthe
activation domain of SF1 (FTZF1) (residues 133–461), 50 ng pCMX-
DAX1 expression vector containing the full-length wild-type or mu-
tantcDNA,and500ngofaUAS-TK109lucreporter.B,Cotransfection
of human SF1 (20 ng) with rat Egr-1 (20 ng) produced synergistic
activation of the rat LH gene promoter (154 to 5) (500 ng). The
effect of wild-type DAX-1 and its mutants is shown in the figure. Data
for each mutant are presented as a percentage (SEM) of empty vector
activity (100%).
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adult endocrinologists to be aware of this condition, the
spectrum of its presentation, and the implications of muta-
tional analysis of DAX1 for genetic counseling, carrier de-
tection, and the appropriate management of fertility.
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